{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:21:19Z","timestamp":1792628479577,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n There are concerns about the safety of medications for treatment of attention-deficit\/hyperactivity disorder (ADHD), with mixed evidence on possible cardiovascular risk.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether short-term methylphenidate use is associated with risk of cardiovascular events.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective, population-based cohort study was based on national Swedish registry data. Participants were individuals with ADHD aged 12 to 60 years with dispensed prescriptions of methylphenidate between January 1, 2007, and June 30, 2012. Each person receiving methylphenidate (n\u2009=\u200926\u202f710) was matched on birth date, sex, and county to up to 10 nonusers without ADHD (n\u2009=\u2009225\u202f672). Statistical analyses were performed from September 13, 2022, to May 16, 2023.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Rates of cardiovascular events, including ischemic heart disease, venous thromboembolism, heart failure, or tachyarrhythmias, 1 year before methylphenidate treatment and 6 months after treatment initiation were compared between individuals receiving methylphenidate and matched controls using a bayesian within-individual design. Analyses were stratified by history of cardiovascular events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The cohort included 252\u202f382 individuals (15\u202f442 [57.8% men]; median age, 20 (IQR, 15-31) years). The overall incidence of cardiovascular events was 1.51 per 10\u202f000 person-weeks (95% highest density interval [HDI], 1.35-1.69) for individuals receiving methylphenidate and 0.77 (95% HDI, 0.73-0.82) for the matched controls. Individuals treated with methylphenidate had an 87% posterior probability of having a higher rate of cardiovascular events after treatment initiation (incidence rate ratio [IRR],\u20091.41; 95% HDI, 1.09-1.88) compared with matched controls (IRR, 1.18; 95% HDI, 1.02-1.37). The posterior probabilities were 70% for at least a 10% increased risk of cardiovascular events in individuals receiving methylphenidate vs 49% in matched controls. No difference was found in this risk between individuals with and without a history of cardiovascular disease (IRR, 1.11; 95% HDI, 0.58-2.13).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, individuals receiving methylphenidate had a small increased cardiovascular risk vs matched controls in the 6 months after treatment initiation. However, there was little evidence for an increased risk of 20% or higher and for differences in risk increase between people with and without a history of cardiovascular disease. Therefore, before treatment initiation, careful consideration of the risk-benefit trade-off of methylphenidate would be useful, regardless of cardiovascular history.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.1349","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T11:01:09Z","timestamp":1709722869000},"page":"e241349","source":"Crossref","is-referenced-by-count":32,"title":["Methylphenidate and Short-Term Cardiovascular Risk"],"prefix":"10.1001","volume":"7","author":[{"given":"Miguel","family":"Garcia-Argibay","sequence":"first","affiliation":[{"name":"School of Medical Sciences, \u00d6rebro University, Faculty of Medicine and Health, \u00d6rebro, Sweden"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Christian","family":"B\u00fcrkner","sequence":"additional","affiliation":[{"name":"Cluster of Excellence SimTech, University of Stuttgart, Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lichtenstein","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"D\u2019Onofrio","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"The Department of Psychological and Brain Sciences at Indiana University, Bloomington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Andell","sequence":"additional","affiliation":[{"name":"Unit of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Heart and Vascular Division, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[{"name":"School of Psychology, University of Southampton, Southampton, United Kingdom"},{"name":"Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, United Kingdom"},{"name":"Solent NHS Trust, Southampton, United Kingdom"},{"name":"Hassenfeld Children\u2019s Hospital at NYU Langone, New York University Child Study Center, New York City"},{"name":"DiMePRe-J-Department of Precision and Regenerative Medicine-Jonic Area, University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Larsson","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, \u00d6rebro University, Faculty of Medicine and Health, \u00d6rebro, Sweden"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"issue":"2","key":"zoi240077r1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/ije\/dyt261","article-title":"ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis.","volume":"43","author":"Polanczyk","year":"2014","journal-title":"Int J Epidemiol"},{"key":"zoi240077r2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.neubiorev.2021.01.022","article-title":"The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder.","volume":"128","author":"Faraone","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"zoi240077r3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41398-022-01919-9","article-title":"The role of ADHD genetic risk in mid-to-late life somatic health conditions.","volume":"12","author":"Garcia-Argibay","year":"2022","journal-title":"Transl Psychiatry"},{"issue":"3","key":"zoi240077r4","doi-asserted-by":"publisher","DOI":"10.1002\/jcv2.v3.3","article-title":"Attention-deficit\/hyperactivity disorder is associated with increased risk of cardiovascular diseases: a systematic review and meta-analysis.","volume":"3","author":"Li","year":"2023","journal-title":"JCPP Adv"},{"issue":"4","key":"zoi240077r5","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.v31.4","article-title":"Cardiovascular risk factors in attention-deficit\/hyperactivity disorder: a family design study of Swedish conscripts.","volume":"31","author":"Garcia-Argibay","year":"2022","journal-title":"Int J Methods Psychiatr Res"},{"issue":"1","key":"zoi240077r6","first-page":"1","article-title":"Attention-deficit\/hyperactivity disorder as a risk factor for dementia and mild cognitive impairment: a population-based register study.","volume":"65","author":"Dobrosavljevic","year":"2021","journal-title":"Eur Psychiatry"},{"key":"zoi240077r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105076","article-title":"The association between type 2 diabetes and attention- deficit\/hyperactivity disorder: a systematic review, meta-analysis, and population-based sibling study.","volume":"147","author":"Garcia-Argibay","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"zoi240077r8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1017\/S0033291705006410","article-title":"Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study.","volume":"36","author":"Biederman","year":"2006","journal-title":"Psychol Med"},{"issue":"1","key":"zoi240077r9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/acps.v144.1","article-title":"Healthcare utilization and costs of psychiatric and somatic comorbidities associated with newly diagnosed adult ADHD.","volume":"144","author":"Garcia-Argibay","year":"2021","journal-title":"Acta Psychiatr Scand"},{"issue":"9","key":"zoi240077r10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"zoi240077r11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40263-017-0410-7","article-title":"Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine.","volume":"31","author":"Hennissen","year":"2017","journal-title":"CNS Drugs"},{"issue":"6","key":"zoi240077r12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.euroneuro.2012.06.011","article-title":"Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults.","volume":"23","author":"Mick","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"zoi240077r13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2165\/11317630-000000000-00000","article-title":"Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.","volume":"32","author":"McCarthy","year":"2009","journal-title":"Drug Saf"},{"issue":"2","key":"zoi240077r14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1176\/appi.ajp.2011.11010125","article-title":"Methylphenidate and risk of serious cardiovascular events in adults.","volume":"169","author":"Schelleman","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"6","key":"zoi240077r15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1089\/cap.2014.0020","article-title":"Cardiovascular safety of stimulants in children with attention-deficit\/hyperactivity disorder: a nationwide prospective cohort study.","volume":"24","author":"Dalsgaard","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"zoi240077r16","doi-asserted-by":"publisher","first-page":"i2550","DOI":"10.1136\/bmj.i2550","article-title":"Cardiovascular safety of methylphenidate among children and young people with attention-deficit\/hyperactivity disorder (ADHD): nationwide self controlled case series study.","volume":"353","author":"Shin","year":"2016","journal-title":"BMJ"},{"issue":"7","key":"zoi240077r17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/ehjcvp\/pvad028","article-title":"Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study.","volume":"9","author":"Eroglu","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"zoi240077r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.4294","article-title":"Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases.","author":"Zhang","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"zoi240077r19","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1542\/peds.2010-3371","article-title":"Cardiovascular events and death in children exposed and unexposed to ADHD agents.","volume":"127","author":"Schelleman","year":"2011","journal-title":"Pediatrics"},{"issue":"20","key":"zoi240077r20","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1056\/NEJMoa1110212","article-title":"ADHD drugs and serious cardiovascular events in children and young adults.","volume":"365","author":"Cooper","year":"2011","journal-title":"N Engl J Med"},{"key":"zoi240077r21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4627","article-title":"Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.","volume":"345","author":"Winterstein","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"zoi240077r22","doi-asserted-by":"publisher","first-page":"e1494","DOI":"10.1542\/peds.2007-0675","article-title":"Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit\/hyperactivity disorder.","volume":"120","author":"Winterstein","year":"2007","journal-title":"Pediatrics"},{"issue":"24","key":"zoi240077r23","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2011.1830","article-title":"ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.","volume":"306","author":"Habel","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"zoi240077r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43597","article-title":"Risk of cardiovascular diseases associated with medications used in attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis.","volume":"5","author":"Zhang","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"452","key":"zoi240077r25","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2307\/2669779","article-title":"Hypothesis testing: from P values to Bayes factors.","volume":"95","author":"Marden","year":"2000","journal-title":"J Am Stat Assoc"},{"key":"zoi240077r26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3389\/fnhum.2017.00390","article-title":"When null hypothesis significance testing is unsuitable for research: a reassessment.","volume":"11","author":"Szucs","year":"2017","journal-title":"Front Hum Neurosci"},{"issue":"1","key":"zoi240077r27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12888-018-1761-4","article-title":"Bayesian alternatives for common null-hypothesis significance tests in psychiatry: a non-technical guide using JASP.","volume":"18","author":"Quintana","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"1","key":"zoi240077r28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3758\/s13423-017-1343-3","article-title":"Bayesian inference for psychology. part I: theoretical advantages and practical ramifications.","volume":"25","author":"Wagenmakers","year":"2018","journal-title":"Psychon Bull Rev"},{"issue":"12","key":"zoi240077r29","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/aje\/153.12.1222","article-title":"Commentary: practical advantages of bayesian analysis of epidemiologic data.","volume":"153","author":"Dunson","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"8","key":"zoi240077r31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"11","key":"zoi240077r32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"issue":"8","key":"zoi240077r33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S2215-0366(19)30189-0","article-title":"Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study.","volume":"6","author":"Hollis","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"zoi240077r34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v076.i01","article-title":"Stan: a probabilistic programming language.","volume":"76","author":"Carpenter","year":"2017","journal-title":"J Stat Softw"},{"issue":"1","key":"zoi240077r35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.32614\/RJ-2018-017","article-title":"Advanced bayesian multilevel modeling with the R Package brms.","volume":"10","author":"B\u00fcrkner","year":"2018","journal-title":"R J"},{"issue":"10","key":"zoi240077r37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.biopsych.2006.04.022","article-title":"Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function.","volume":"60","author":"Berridge","year":"2006","journal-title":"Biol Psychiatry"},{"issue":"3-4","key":"zoi240077r38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ando.2020.03.012","article-title":"Adrenergic receptors and cardiovascular effects of catecholamines.","volume":"82","author":"Motiejunaite","year":"2021","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"zoi240077r39","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1113\/tjp.2017.595.issue-3","article-title":"Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis.","volume":"595","author":"Adlan","year":"2017","journal-title":"J Physiol"},{"issue":"1","key":"zoi240077r40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register.","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"zoi240077r30","doi-asserted-by":"crossref","DOI":"10.1201\/9781315372495","volume-title":"Statistical Rethinking: A Bayesian Course With Examples in R and Stan","author":"McElreath","year":"2018"},{"key":"zoi240077r36","unstructured":"R Development Core Team. R: a language and environment for statistical computing. 2020. Accessed November 13, 2022. http:\/\/www.R-project.org"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2815765\/garciaargibay_2024_oi_240077_1708699211.00112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T11:01:15Z","timestamp":1709722875000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2815765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.1349","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}